EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-tablet oxybutynin system for treating incontinence



Multi-tablet oxybutynin system for treating incontinence



Official Gazette of the United States Patent & Trademark Office Patents 1247(3), June 19



The present invention provides a simple multi-tablet system for the treatment of urinary incontinence with oxybutynin. Particular embodiments of the invention provide a first tablet that releases oxybutynin over a short period of time, e.g. less than six hours, and a second tablet that releases oxybutynin over an extended period of time, e.g., eighteen to twenty-four hours, to maintain therapeutically effective levels oxybutynin in the mammal for a period of about twenty four hours. Unlike other systems, this system is easily adaptable to compensate for patient to patient variability in response to oxybutynin therapy. The invention also provides a method of treating urinary incontinence with the above system and a kit comprising various first and second tablets to rapidly develop a patient's preferred dosing regimen, i.e., the dosing regimen which provides the greatest therapeutic benefit and/or least amount or severity of side effects.

(PDF 0-2 workdays service: $29.90)

Accession: 035349608

Download citation: RISBibTeXText



Related references

Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourology & Urodynamics. 16(6): 533-542, 1997

Treating urinary incontinence with -desethyloxybutynin and -oxybutynin. Official Gazette of the United States Patent & Trademark Office Patents 1238(4), Sep 26, 2000

Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. Bju International 87(9): 767-773, 2001

Methods and compositions for treating urinary incontinence using optically pure -oxybutynin. Official Gazette of the United States Patent & Trademark Office Patents 1188(1): 445, July 2, 1996

Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. Journal of Urology 161(6): 1809-1812, 1999

Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. Urology 68(4): 862-865, 2006

A novel multi-unit tablet for treating circadian rhythm diseases. Aaps Pharmscitech 14(2): 861-869, 2013

Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. Neurourology and Urodynamics 33(5): 482-487, 2015

Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 74(4): 741-745, 2009

Clinical effect of oxybutynin hydrochloride (1 mg/tablet). Hinyokika Kiyo. Acta Urologica Japonica 36(7): 869-876, 1990

Intravesical oxybutynin: Mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin. Journal of Urology 166(6): 2232-2236, December, 2001

Pharmacokinetics and pharmacodynamics of oxybutynin and N-desethyl oxybutynin following oxybutynin administration by oral and intravesical routes. Journal of Urology 165(5 Supplement): 276, 2001

Effect of ketoconazole on the pharmacokinetics of oxybutynin Comparison between an extended release oxybutynin and conventional oxybutynin. Neurourology & Urodynamics 18(4): 374-375, 1999